Secarna Pharmaceuticals is the next generation antisense oligonucleotide (ASO) company with multiple innovative antisense therapies in various stages of pre-clinical development in the areas of immuno-oncology, immunology, ophthalmology, as well as viral-, neurodegenerative- and cardiometabolic diseases. Secarna’s mission is to maximize the performance and output of its proprietary LNAplus? antisense oligonucleotide discovery platform, as well as to develop highly specific, safe, and efficacious best-in-class antisense therapies for challenging or currently not druggable targets. www.secarna.com